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Human surfactant protein D (SP-D) belongs to the family of collectins that is composed
of a characteristic amino-terminal collagenous region and a carboxy-terminal C-type
lectin domain. Being present at the mucosal surfaces, SP-D acts as a potent innate
immune molecule and offers protection against non-self and altered self, such as
pathogens, allergens, and tumor. Here, we examined the effect of a recombinant
fragment of human SP-D (rfhSP-D) on a range of breast cancer lines. Breast cancer
has four molecular subtypes characterized by varied expressions of estrogen (ER),
progesterone (PR), and epidermal growth factor (EGF) receptors (HER2). The cell viability
of HER2-overexpressing (SKBR3) and triple-positive (BT474) breast cancer cell lines
[but not of a triple-negative cell line (BT20)] was reduced following rfhSP-D treatment
at 24 h. Upregulation of p21/p27 cell cycle inhibitors and p53 phosphorylation (Ser15)
in rfhSP-D-treated BT474 and SKBR3 cell lines signified G2/M cell cycle arrest. Cleaved
caspases 9 and 3 were detected in rfhSP-D-treated BT474 and SKBR3 cells, suggesting
an involvement of the intrinsic apoptosis pathway. However, rfhSP-D-induced apoptosis
was nullified in the presence of hyaluronic acid (HA) whose increased level in breast
tumor microenvironment is associated with malignant tumor progression and invasion.
rfhSP-D bound to solid-phase HA and promoted tumor cell proliferation. rfhSP-D-treated
SKBR3 cells in the presence of HA showed decreased transcriptional levels of p53
when compared to cells treated with rfhSP-D only. Thus, HA appears to negate the
anti-tumorigenic properties of rfhSP-D against HER2-overexpressing and triple-positive
breast cancer cells.
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INTRODUCTION
The immune surveillance of transformed cells by innate and
adaptive immunity remains one of the targeted areas of
research for developing therapeutic strategies (1, 2). In vivo
and in vitro studies using cancer models have demonstrated
compelling involvement of effector immune cells, soluble factors,
and signaling pathways in anti-tumor immune responses.
However, the immune system can also aid in the progression
of transformed cells by triggering immunosuppression and
promoting angiogenesis and metastasis of tumor cells (3, 4).
Human surfactant protein D (SP-D) is a potent innate
immune molecule found at pulmonary and non-pulmonary
mucosal surfaces (5). It is a member of the collectin family that
is involved in the clearance of pathogens and apoptotic/necrotic
cells and in the modulation of inflammatory responses (6).
SP-D is composed of an N-terminal cysteine-rich domain, a
triple-helical collagenous region, an α-helical coiled neck region,
and a C-terminal C-type lectin or carbohydrate recognition
domain (CRD) (7). The trimeric CRDs recognize carbohydrate or
charged patterns on pathogens and allergens, while the collagen
region is involved in interactions with receptor molecules present
on immune cells in order to trigger clearance mechanisms such
as agglutination, enhanced phagocytosis, and oxidative burst (6).
SP-D is primarily synthesized and secreted into the airspace
of the lungs by alveolar type II and Clara cells, with a key
role in surfactant homeostasis by reducing surface tension (6).
However, its extrapulmonary existence is well-established now,
ranging from themucosa of the gastrointestinal and reproductive
tracts (including ovaries) and nasal cavity to the brain and in
various exocrine ducts (8, 9), conjunctiva, cornea, lacrimal gland,
nasolacrimal ducts (8), and synovial fluid (10). Protective effects
of SP-D against a range of pathogens (6, 11) and allergens (12–16)
are well-documented in the literature. However, recent studies
have raised the possibility that SP-D may have an important
defense role against tumor.
A direct interaction of SP-D with a number of cancer cells
(leukemia, lung, prostate, and pancreatic) has been reported to
result in the suppression of cancer progression, migration, and
invasion, as well as enhanced apoptosis (17–21). The rfhSP-D-
treated acute myeloid leukemia (AML) cells were shown to result
in cell cycle arrest via activation of G2/M checkpoints, with an
increased level of p21 and Try15 phosphorylation of cdc2. rfhSP-
D treatment in AML cells also caused activation of pro-apoptotic
markers, such as cleaved caspase 9 and downregulation of pro-
survival protein HMGA1 (21, 22). Exogenous SP-D treatment
has been shown to downregulate epidermal growth factor (EGF)
signaling by preventing the binding of EGF to the EGF receptor
(EGFR), hence suppressing the cell proliferation, invasion, and
migration of A549 human lung adenocarcinoma cells (23).
Recently, rfhSP-D has been shown to induce apoptosis in p53
mutant (mt) and wild-type (wt) pancreatic adenocarcinoma
(PDAC) cell lines (Panc-1p53 mt, MiaPaCa-2p53 mt, and Capan-
2p53wt), via the TNF/Fas-mediated extrinsic pathway (17).
Furthermore, rfhSP-D can also suppress epithelial–mesenchymal
transition (EMT) and related gene signatures (Vimentin, Zeb1,
and Snail) and cell invasiveness in Panc-1 andMiaPaCa-2 cells via
downregulation of TGF-β (24). In an ovarian cell line, SKOV3,
rfhSP-D again triggered apoptosis via the Fas-mediated pathway
(18). In both pancreatic and ovarian cancer cell lines, rfhSP-D
treatment caused activation of caspase 3 cleavage and induction
of pro-apoptotic genes such as Fas and TNF-α. Furthermore, the
mTOR pathway was also affected by rfhSP-D treatment in both
ovarian and pancreatic cancer cell lines. rfhSP-D-treated SKOV3
cells show downregulation of Rictor and Raptor mRNA levels,
suggesting inhibition of cell proliferation (17, 18). Additionally,
the anti-tumor role of rfhSP-D has been reported in androgen-
resistant and androgen-responsive prostate cancer cells via p53
and pAkt pathways (19). In a recent bioinformatics study, a
higher expression of SP-D in ovarian and lung cancer was found
to be associated with a favorable prognosis (20). These studies
therefore suggest that SP-D has an immune surveillance function
against tumor cells. In this context, this study was aimed at
investigating the role of SP-D in breast cancer.
Breast cancer is the most common cancer diagnosed in
women worldwide, contributing to almost 60% mortality rate
in lower-income countries (25). There is a large variation in
the survival rates worldwide, with an estimated 5-year survival
rate of 80% in developed countries and below ∼40% in low-
income countries (26). Designing effective treatments are crucial
to improve the survival rates and to ensure the best possible
quality of life for cancer survivors. After lung cancer, breast
carcinomas are the second most leading cause of mortality
(27); ∼17.5 million new cases of breast cancer are diagnosed
globally, and 8.7 million deaths documented (28). As per
GLOBOCAN 2018, ∼2 million new cases were identified, and
6.6% of cancer-related deaths were caused by breast cancer.
Furthermore, the 5-year prevalence rate of breast cancer was
found to be ∼6.8 million (25). Breast cancer is characterized by
an abnormal growth of malignant cells in the mammary glands.
The physiological conditions that lead to breast tumorigenesis
include inherited genetic mutation and epigenetic modifications,
which can lead to premalignant transformation of mammary
cells (29). The development of advanced breast tumor is a
consequence of immune selection and immune evasion (30).
Breast cancer is subdivided into different molecular subtypes:
luminal A, luminal B, triple negative, human EGF receptor
(HER)2-enriched, basal, and normal-like tumors (31, 32).
The development and metastasis of cancer, including breast
cancer, appear to be influenced by innate immune surveillance
molecules and associated inflammatory mediators in the tumor
microenvironment (33, 34).
Here, we examined possible protective effects of rfhSP-
D in triple-negative (ER−/PR−/HER2−), triple-positive
(ER+/PR+/HER2+), and HER2+-overexpressing breast
cancer cell lines. We also examined a possible interaction
between SP-D and hyaluronic acid (HA; polymeric nonsulfated
glycosaminoglycan), the most abundant component of the
extracellular matrix (ECM), which plays an important role in
inflammation, angiogenesis, fibrosis, and cancer progression
(35). The interaction of breast cancer cells with HA can sustain
tumor growth and promote malignant progression. The altered
synthesis of HA in early and late stages of ductal breast carcinoma
in situ (DCIS) microenvironment is correlated with tumor stage
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progression and invasion (36). Several studies provide strong
evidence that HA participates in the regulation of breast tumor
cell migration and invasion in vitro and tumor growth and
progression in vivo (37–39). We report, for the first time, that
rfhSP-D interacts with HA that negates its anti-tumor properties;
i.e., in the presence of HA, rfhSP-D is unable to induce apoptosis
in triple-positive and HER2-overexpressing breast cancer cell
lines. Therefore, neutralizing the negative effect of HA on
rfhSP-D can have crucial implications for the development of
therapeutic strategies.
MATERIALS AND METHODS
Expression and Purification of rfhSP-D
Expression and purification of rfhSP-D were performed as
published earlier (19). Briefly, Escherichia coli BL21 (λDE3)
pLysS bacterial strain (Invitrogen) was transformed with plasmid
pUK-D1, composed of cDNA sequences for α-helical neck
and CRD region of human SP-D. Twenty-five milliliters of
bacterial primary inoculum was inoculated into 500 ml of Luria-
Bertani medium containing 100 µg/ml ampicillin and 34 µg/ml
chloramphenicol (Sigma-Aldrich) and grown to anOD600 of 0.6.
The bacterial cells were then induced with 0.5 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3 h.
The IPTG-induced bacterial cell pellet was treated with lysis
buffer (50 mM Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA
pH 8, 0.1% v/v Triton X-100, 0.1 mM phenyl-methyl-sulfonyl
fluoride, 50 µg/ml lysozyme) and subsequently sonicated (five
cycles, 30 s each). The sonicated was centrifuged at 12,000 × g
for 30 min, followed by denaturation and renaturation of rfhSP-
D inclusion bodies using refolding buffer (50 mM Tris–HCl
pH 7.5, 100 mM NaCl, 10 mM 2-mercaptoethanol) containing
8 M urea. The dialysate was then loaded onto a maltose–
agarose affinity column (5 ml; Sigma-Aldrich), and rfhSP-D was
eluted using 10 mM EDTA buffer containing 50 mM Tris–HCl
pH 7.5 and 100 mM NaCl. Eluted rfhSP-D fractions were then
tested for endotoxin levels using a QCL-1000 Limulus amebocyte
lysate system (Lonza). The endotoxin levels were found to be
∼5 pg/µg of rfhSP-D. The purity of protein was analyzed via
15% w/v SDS-PAGE, and its immunoreactivity was assessed via
western blotting.
Cell Culture and Treatments
Human breast cancer cell lines, triple-negative BT20
(ER−/PR−/HER2−) (ATCC-HTB19), triple-positive BT474
(ER+/PR+/HER2+) (ATCC-HTB20), and HER2-positive
SKBR3 (ER−/PR−/HER2+) (ATCC-HTB30), were cultured
in complete RPMI medium (Sigma-Aldrich), supplemented
with 10% v/v fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin (Sigma-Aldrich), 100 µg/ml streptomycin
(Sigma-Aldrich), and 1 mM sodium pyruvate (Sigma-Aldrich)
and left to grow at 37◦C under 5% v/v CO2. Since these cell
lines were adherent, cells were detached using 2× trypsin–EDTA
(0.5%) (Fisher Scientific) for 10 min at 37◦C, then centrifuged
at 1,500 rpm for 5 min, and resuspended in complete RPMI.
Cell number and viability were assessed by mixing an equal
volume of the cell suspension and Trypan Blue (0.4% w/v)
(Fisher Scientific) and by counting using a hemocytometer with
a Neubauer chamber (Sigma-Aldrich).
Fluorescence Microscopy
BT20, BT474, and SKBR3 (50,000) cells were grown on coverslips
and incubated with rfhSP-D (10 µg/ml) in serum-free RPMI
medium for 1 h for cell binding analysis and 24 h for
apoptosis induction. For binding experiments, the coverslips
were washed three times with phosphate-buffered saline (PBS)
and incubated with polyclonal anti-rabbit human SP-D antibody
(1:200) (Medical Research Council Immunochemistry Unit,
Oxford) for 1 h at room temperature (RT). Following washes
with PBS, the cells were incubated with goat anti-rabbit IgG
conjugated to Alexa Fluor R© 488 (1:200) (Abcam) and Hoechst
(1:10,000) (Sigma-Aldrich) for immunofluorescence analysis. For
apoptosis induction analysis, the cells were incubated with FITC
Annexin V (1:200) and propidium iodide (PI) (1:200) diluted in
AnnexinV-binding buffer for 15min at RT in dark. After washing
with PBS three times, the coverslips were mounted on slides and
viewed under an HF14 Leica DM4000 microscope.
Flow Cytometry
BT20, BT474, and SKBR3 (0.4 × 106) cells were grown in a six-
well-plate and incubated with rfhSP-D (20 µg/ml), along with an
untreated control, for 24 h. The cells were then detached using
2 × trypsin–EDTA (0.5%) (Fisher Scientific) and centrifuged at
1,500 × g for 5 min. Staurosporine (1 µM/ml; Sigma-Aldrich)
was used as a positive control of apoptosis. Following washes
with PBS, the cells were incubated for 15 min with goat anti-
rabbit IgG conjugated to Alexa Fluor R© 488 (1:200) (Abcam) and
Hoechst (1:10,000) (Sigma-Aldrich) for apoptosis analysis. After
washing with PBS three times, apoptosis was measured using
a NovoCyte flow cytometer. Compensation parameters were
acquired using unstained, untreated FITC-stained, and untreated
PI-stained cells for all three cell lines. For solid-phase studies, six-
well-plates were coated with HA (20 µg/ml) (a kind gift from
Prof. Ivan Donati, Department of Life Sciences, University of
Trieste) overnight at 4◦C with and without rfhSP-D (20 µg/ml).
The wells were washed with PBS, and 0.4 × 106 cells were
added to the HA/rfhSP-D-coated wells and incubated 37◦C for
24 h. For proliferative studies, the cells were washed with PBS
and incubated with anti-mouse Ki-67 (BioLegend) diluted in a
permeabilization reagent of the FIX&PERMkit (Fisher Scientific)
for 30 min at RT. After PBS washes, the cells were probed
with a goat anti-mouse-FITC conjugate (1:200) (Fisher Scientific)
for 30 min at RT in the dark. Cells (12,000) were acquired
for each experiment and compensated before plotting the
acquired data.
Purification of Full-Length SP-D From
Breast Cancer Cell Lines
BT20, BT474, and SKBR3 (0.4 × 106) culture media were
collected and centrifuged at 5,000 rpm for 10 min. The
supernatants were passed through a maltose–agarose affinity
column. The bound full-length SP-D was eluted using an elution
buffer, containing 50 mM Tris–HCl pH 7.5, 100 mM NaCl,
and 10 mM EDTA. Full-length SP-D protein yield of 1 µg/ml
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was obtained from 100 ml of culture medium. The purity of
eluted fractions (10µg/ml) was analyzed via 15%w/v SDS-PAGE,
and its immunoreactivity was determined via western blotting.
For western blotting analysis, the eluted full-length SP-D was
heated for 10 min at 100◦C and subjected to SDS-PAGE (12%
v/v). The proteins were then electrophoretically transferred onto
a nitrocellulose membrane (320 mA for 2 h) in 1× transfer
buffer (25 mM Tris–HCl pH 7.5, 190 mM glycine, and 20%
methanol). The membrane was blocked using 5% w/v dried milk
powder (Sigma-Aldrich) in PBS overnight at 4◦C, followed by
washing with PBS three times for 5 min each. The membrane was
then incubated with polyclonal anti-rabbit human SP-D antibody
(MRC Immunohistochemistry Unit, Oxford) (1:1,000), followed
by probing with protein A–HRP (Sigma-Aldrich) (1:1,000).
Following washing with PBST, the membrane was developed
using a 3′-diaminobenzidine (DAB) substrate kit.
Apoptosis Analysis of Breast Cancer Cells
Treated With BT474-Derived Full-Length
SP-D
The purified full-length SP-D from breast cancer culture was
subjected to apoptosis assay using an Annexin V/FITC kit
(BioLegend). BT20, BT474, and SKBR3 cells (0.4 × 106) were
incubated with 20 µg/ml of culture-purified SP-D and incubated
for 24 h. The cells were then detached using 2 × trypsin–
EDTA (0.5%) (Fisher Scientific) and centrifuged at 1,500 × g
for 5 min. Following washes, the cells were then incubated
with both FITC and PI dye (1:200) for 15 min in the dark.
After washing with PBS, the cells were subjected to flow
cytometric analysis. Compensation parameters were acquired
using unstained, untreated FITC-stained, and untreated PI-
stained cells for all three cell lines.
Immunohistochemical Analysis
Surgical breast cancer tissues and adjacent peritumoral
mammary parenchymas were selected following ethical
approval by the University Hospital of Palermo Ethical Review
Board (approval number 09/2018). TNBC, HER2+, luminal B,
and luminal A breast cancer tissues were used, while normal
breast tissue was used as a control. Immunohistochemistry
(IHC) was performed using a polymer detection method. Briefly,
tissue samples were fixed in 10% v/v buffered formalin and
paraffin embedded. Four-micrometer-thick tissue sections were
deparaffinized and rehydrated. The antigen unmasking technique
was carried out using Novocastra Epitope Retrieval Solutions,
pH 6 EDTA based (Leica Biosystems), in a thermostatic bath
at 98◦C for 30 min. Sections were brought to RT and washed
in PBS. After neutralization of the endogenous peroxidase with
3% v/v H2O2 and Fc blocking (Novocastra, Leica Biosystems),
the samples were incubated overnight at 4◦C with mouse
anti-human SP-D monoclonal antibody (1:800) (Abcam).
Staining was revealed via a polymer detection kit (Novocastra,
Leica Biosystems) and 3-amino-9-ethylcarbazole (AEC, Dako,
Denmark) substrate chromogen. Slides were counterstained
with Harris hematoxylin (Novocastra, Leica Biosystems). Alcian
blue staining was carried out to detect the presence of mucins
in breast cancer tissue sections, according to the manufacturer’s
kit Bioptica (04-160802). Slides were analyzed under the Axio
Scope A1 optical microscope (Zeiss) and microphotographs were
collected through the Axiocam 503 color digital camera (Zeiss)
using the Zen 2 software.
Adhesion Assay
BT20, BT474, and SKBR3 (0.5 × 105) cells were labeled with
FAST DiI fluorescent dye (Molecular Probes, Invitrogen) and
allowed to adhere to 96microtiter wells pre-coated with 20µg/ml
of HA, rfhSP-D, and bovine serum albumin (BSA). The adhesion
of cells was measured after 35 min of incubation at 37◦C under
5% CO2. The non-adhered cells were washed off with PBS,
and the remaining cells were lysed using 10 mM Tris–HCl pH
7.4 + 0.1% v/v SDS. The plate was read at 544 nm using Infinite
200 (Tecan). Results were expressed as adhesion percentage with
reference to a standard curve established using an increasing
number of FAST DiI-labeled cells.
Intracellular Signaling Analysis
Signaling pathway was analyzed using the PathScan Intracellular
Signaling Array Kit (Cell Signaling Technology). Briefly,
0.5 × 106 breast cancer cell lines were grown in a six-well-plate
in serum-free RPMI medium. Cells were then left to adhere to
HA and rfhSP-D (20 µg/ml) pre-coated plates and incubated at
37◦C for 25 min. The unbound cells were then washed with cold
PBS and lysed in ice-cold cell lysis buffer containing a cocktail
of protease inhibitors (Roche Diagnostics). The Array Diluent
Blocking buffer was added to each well on themulti-well gasket at
RT for 15min. After decanting the Array Blocking Buffer, 75µl of
the total lysate (0.8 mg/ml) was added to each well and incubated
for 2 h at RT on an orbital shaker. The well contents were
decanted and washed with 100 µl of 1× Array Wash Buffer three
times (5 min each wash). The wells were then incubated with
biotinylated detection cocktail antibody for 1 h at RT, followed by
incubation with streptavidin-conjugated DyLight 680 for 30 min.
The fluorescence readout was measured via LI-COR Biosciences
Infrared Odyssey imaging system (Millennium Science), and data
were processed by the software Image Studio 5.0.
Western Blotting
BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a
six-well-plate and treated with rfhSP-D (20 µg/ml) for 24 h,
along with an untreated control, in a serum-free RPMI medium.
After removing the medium, the cells were lysed using a lysis
buffer (50 mM Tris–HCl pH 6.8, 2% v/v SDS, 2% v/v β-
mercaptoethanol, 10% v/v glycerol and 0.1% w/v bromophenol
blue). The lysed cells were then sonicated for 15 s, and the
sonicated samples were heated for 10 min at 100◦C and
subjected to SDS-PAGE (12% v/v). The proteins were then
electrophoretically transferred onto a nitrocellulose membrane
(320 mA for 2 h) in 1× transfer buffer (25 mM Tris–HCl pH
7.5, 190 mM glycine, and 20% v/v methanol). The membrane
was blocked using 5% w/v dried milk powder (Sigma-Aldrich) in
PBS overnight at 4◦C, followed by washing with PBS three times
(5 min each). For apoptosis studies, the membrane was incubated
with rabbit anti-human caspase primary antibodies (anti-cleaved
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caspase 9 and anti-cleaved caspase 3; Cell Signaling) at RT for 1 h.
The membrane was washed with PBST (PBS+ 0.05% Tween 20)
three times, 10 min each, followed by incubation with secondary
goat anti-rabbit IgG horseradish peroxidase (HRP) conjugate
(1:1,000; Fisher Scientific) for 1 h at RT. Following washes with
PBST, the membrane was developed using a DAB substrate kit
(Thermo Fisher).
ELISA
For HA (1,500 kDa) binding analysis, a constant concentration
of HA (20 µg/ml) was coated overnight at 4◦C using
carbonate/bicarbonate (CBC) pH 9.6 buffer, followed by blocking
with 2% w/v BSA at 37◦C. Recombinant maltose binding protein
(MBP) was used as a negative control in this experiment.
After three washes with PBST, rfhSP-D (5, 10, or 20 µg/ml)
was incubated in buffer containing 5 mM CaCl2 for 2 h
at 37◦C. After washing with PBST three times, the binding
was assessed by polyclonal anti-rabbit human SP-D antibody
(1:5,000) and incubated at 37◦C for 1 h. The wells were washed
again with PBST three times and incubated with protein A–
HRP secondary conjugate (1:5,000) (Sigma-Aldrich) for 1 h at
37◦C. After washes with PBST, the binding was detected using
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich).
The reaction was stopped using 2 N H2SO4, and the absorbance
was read at 450 nm using an iMarkTM microplate absorbance
reader (Bio-Rad).
Quantitative RT-PCR
BT20, BT474, and SKBR3 (0.4 × 106) cells were added to
six-well-plate pre-coated with HA (20 µg/ml), HA + rfhSP-D
(20 µg/ml), and rfhSP-D (20 µg/ml) and incubated at 37◦C
for various time points. The cell pellet for each time point
was subjected to RNA extraction using GenElute Mammalian
Total RNA Purification Kit (Sigma-Aldrich). RNA samples were
then treated with DNase I (Sigma-Aldrich), and the total RNA
concentration and purity were determined using a 260:280 nm
ratio using NanoDrop 2000/2000c (Thermo Fisher Scientific).
Two micrograms of total RNA was used for cDNA synthesis
using High Capacity RNA to cDNA kit (Applied Biosystems).
Primer sequences used in this study were designed for specificity
using the Primer-BLAST software (Basic Local Alignment
Search Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). p21 and
p27 mRNA levels were estimated by quantitative RT-PCR (qRT-
PCR) using the following primers: 5′-TGGAGACTCTCAGGG
TCGAAA-3′ and 5′-CGGCGTTTGGAGTGGTAGAA-3′ for p21,
and 5′-CCGGTGGACCACGAAGAGT-3′ and 5′-GCTCGCCTC
TTCCATGTCTC-3′ for p27. Briefly, the qPCR reaction consisted
of 5 µl of iQ SYBR Green Supermix (Bio-Rad, Milan, Italy),
75 nM of forward and reverse primers, and 500 ng template
cDNA in a 10 µl final reaction volume. qRT-PCR was performed
on a Rotor-Gene 6000 (Corbett, Explera, Ancona, Italy). The
melting curve of the reactions was recorded between 55 and
99◦C with a hold every 2 s. The comparative quantification
(CQ) method was used to determine the relative amount of gene
expression in each sample, and the data analyzed using Rotor-
Gene 1.7 software (Corbett Research) (40). The CQ method
is specific in calculating the efficiencies of each gene for each
individual PCR and is based on the second differential maximum
method. The samples were normalized using the expression
of human TATA binding protein (TBP) rRNA. Assays were
conducted in triplicates.
Statistical Analysis
Graphs were generated using GraphPad Prism 6.0; the statistical
analysis was carried out using an unpaired one-way ANOVA test.
Error bars represent SD or SEM (n = 3), as indicated in the
figure legends. The significant values were measured based on
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001 between
treated and untreated samples.
RESULTS
A Recombinant Form of Truncated Human
SP-D Binds Breast Cancer Cell Lines
rfhSP-D comprising the eight Gly-X-Y repeats and the neck
and CRD regions of human SP-D was affinity-purified and
migrated at ∼20 kDa on SDS-PAGE under reducing conditions
(Figure 1A). The immunoreactivity of purified rfhSP-D was
confirmed via western blotting using polyclonal anti-human
SP-D antibody raised in rabbit against native human SP-D
purified from lung lavage (Figure 1B). BSA was used as a
negative control protein. Purified rfhSP-D (5 µg/ml) bound
breast cancer cell lines, triple-negative BT20 (ER−/PR−/HER2−),
triple-positive BT474 (ER+/PR+/HER2+), and HER2-positive
SKBR3 (ER−/PR−/HER2+) (Figure 1D). The nucleus of the cell
was stained with Hoechst dye, while the membrane localization
of the bound rfhSP-D was revealed using green FITC/anti-
human SP-D conjugate. All rfhSP-D-treated breast cancer cell
lines showed a similar “cluster”-like binding pattern on the cell
membrane (Figure 1D). No FITC was detected in the untreated
controls (Figure 1C), probed with both primary and secondary
antibodies, suggesting the specificity of rfhSP-D binding.
Apoptosis Induction by rfhSP-D in Breast
Cancer Cell Lines
The quantitative and qualitative analyses of apoptosis induction
by rfhSP-D were performed using flow cytometry (Figures 2A,B)
and immunofluorescence microscopy (Figures 2C,D). A
significant proportion of BT474 and SKBR3 breast cancer cells
treated with rfhSP-D (20 µg/ml) underwent apoptosis at 24 h
as revealed by FACS analysis (Table 1). BT474 (∼61%) and
SKBR3 (∼68%) cell lines were more susceptible to apoptosis
induction when immobilized rfhSP-D (20 µg/ml) (Figure 2A)
was used; there was no effect on the BT20 cell line. rfhSP-D in
solution also induced apoptosis in BT474 (∼34%) and SKBR3
(∼53%) (Figure 2B); again, rfhSP-D had no significant effect on
the BT20 cell line (Figure 2A, Table 1). The integrity of the cell
membrane was intact in untreated cells, and hence, the cells were
still viable, blocking the translocation of phosphatidylserine (PS)
from the inner cell membrane to outer plasma membrane and
preventing the PS–Annexin V interaction. Nearly 56% BT474
and SKBR3 cells were both stained positive for FITC and PI,
suggesting that annexin V/FITC was able to bind to PS found
on the cell surface of the cells undergoing apoptosis. However,
there were more BT474 cells that stained for PI alone than the
SKBR3 cell line, suggesting that BT474 cells were either at the
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FIGURE 1 | SDS-PAGE (A) and immunoblot profile (B) of the purified
recombinant form of human surfactant protein D (rfhSP-D). Expression of
rfhSP-D under the bacteriophage T7 promoter, expressed as ∼20 kDa
insoluble protein. Eluted fractions were passed through a maltose–agarose
column, which appeared as a single band at ∼20 kDa. Immunoreactivity of
(Continued)
FIGURE 1 | affinity-purified rfhSP-D was examined via western blotting; lane
1: BSA as a negative control; lane 2: purified rfhSP-D (5 µg/ml). Binding of
rfhSP-D (10 µg/ml) to breast cancer cell lines using fluorescence microscopy,
following 1 h incubation at 4◦C (C,D). The nucleus of the cells was stained with
Hoechst (1:10,000), and both untreated (cells only) (C) and rfhSP-D-treated
(D) cells were probed with polyclonal anti-human SP-D/FITC antibody (1:200).
Membrane localization of the bound proteins was only detected in the treated
cells, while no FITC was detected in the untreated control (cells only).
late stage of apoptosis or undergoing necrosis. The percentage of
viable cells in the untreated (cells only) sample was significantly
higher as compared to the treated sample, BT474 (∼92%)
and SKBR3 (∼96%), suggesting that apoptosis induction was
a rfhSP-D protein-specific effect (Figure 2A). Staurosporine
(1 µM/ml) was used as a positive control for apoptosis studies.
Staurosporine-treated BT20, BT474, and SKBR3 showed ∼70%
of apoptosis induction at 24 h (Figures 2A,B). Staurosporine
is a well-known therapeutic, potent apoptosis inducer, which
is suggested to inhibit tumor cell growth and proliferation by
triggering cell death via an intrinsic apoptotic pathway (41).
Fluorescence microscopy analysis in BT474 and SKBR3 cell
lines treated with rfhSP-D revealed a positive staining for cell
membrane integrity marker, Annexin V (conjugated to FITC),
and disoriented cell membrane morphology (Figures 2C,D).
Thus, PI-positive staining was seen only in treated cell lines
(Figure 2D) compared to untreated control cells (Figure 2C),
indicating no occurrence of late apoptotic or necrosis. In
contrast, no positive staining of Annexin V or PI was detected in
BT20 treated cells, which were similar to the untreated control.
rfhSP-D Induces Apoptosis in BT474 and
SKBR3 Cell Lines via Intrinsic Pathway
Since rfhSP-D caused apoptosis in BT474 and SKBR3 cells, we
further examined the likely apoptotic pathway being triggered
following rfhSP-D treatment. Apoptosis can be initiated through
intrinsic or extrinsic pathways. Expression of caspases was tested
in rfhSP-D-treated breast cancer cell lines. Western blotting
analysis of rfhSP-D-treated BT474 and SKBR3 cells at 24 h
revealed cleavage of caspase 9 (∼37 kDa) and 3 (∼17 kDa),
suggesting the involvement of the intrinsic apoptosis pathway
(Figure 3). As expected, cleavage of caspases 3 (Figure 3A) and
9 (Figure 3B) was not detected in BT20 and untreated (cells
only) controls. Furthermore, cleaved caspase 8 was tested as a
marker for the extrinsic pathway, but no difference was observed
between rfhSP-D-treated cell lines and untreated controls (data
not shown).
Expression of Human SP-D and HA in
Breast Cancer Tissues
The expression of human SP-D was analyzed in eight cases of
invasive ductal carcinoma, no special type (NSP), comprising
two cases for each molecular class (luminal A, luminal B,
Her2-Neu, and triple negative) based on the expression of the
estrogen receptor (ER), the progesterone receptor (PR), and the
human EGF receptor 2 (Her2-Neu) status. Among biological
variables considered, besides the different molecular class, the
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FIGURE 2 | Flow cytometric analysis of apoptosis induction in breast cancer
cells treated with 20 µg/ml of immobilized (A) and solution-phase (B) rfhSP-D
for 24 h. For both Annexin V/FITC and DNA/PI staining, 12,000 cells were
acquired and plotted. A significant difference was seen among treated and
untreated (cells only) samples, as evident by the shift in the fluorescence
intensity. The data were expressed as the mean of three independent
experiments (n = 3) done in triplicates ± SEM. Statistical significance was
established using the unpaired one-way ANOVA test (**p < 0.01 and
****p < 0.0001). The percentage of apoptosis was calculated by normalizing
the treated cells with their untreated counterparts. Fluorescence microscopy
analysis of apoptosis induction in breast cancer cells treated with rfhSP-D
(20 µg/ml) for 24 h, using an Annexin V with a propidium iodide (PI) staining kit;
untreated (cells only) controls (C) and rfhSP-D-treated cells (D). The nucleus
(Continued)
FIGURE 2 | was stained with Hoechst (1:10,000), and the cell membrane was
stained positively with Annexin V and PI (1:200) in treated cell lines, suggesting
that cells treated with rfhSP-D induced apoptosis at 24 h, where translocation
of PS to the outer plasma membrane was able to bind Annexin V due to loss
of membrane integrity and PI stain was taken, which stained the DNA of
apoptotic cells. No Annexin V/PI staining was detected in untreated cells.
neoplastic tissues presented a different grade tumor, computed
with the Nottingham score, varying from moderate (G2) to
undifferentiated (G3). Indeed, the molecular classification allows
us to identify four different classes based on the expression
of the ER and PR and the human EGF receptor 2 (Her2-
Neu) status and called luminal A, luminal B, Her2-Neu, and
triple negative, respectively. The molecular subtypes reflect
the neoplastic heterogeneity of breast cancer and differ in
gene expression patterns, clinical and morphological features,
response to treatment, and outcome. Our aim was to evaluate
the presence and distribution of SP-D in all molecular subtypes
of breast cancer to dissect its biological role in neoplastic
progression and to consider a potential predictive and/or
prognostic marker of mammary carcinoma. Our data appear to
suggest heterogeneous inter-tumor and intra-tumor expressions
of SP-D within the molecular subtypes. IHC staining for SP-
D highlighted its cytoplasmic expression in both the neoplastic
tissue and the healthy peritumoral mammary parenchyma, as
previously demonstrated (20). Indeed, the presence of SP-D
was evident in cytoplasmic labeling and was highly expressed
by the ductal epithelium of peritumoral mammary parenchyma
and the neoplastic subclones of luminal A type, while its
reduced expression was evident in triple-negative breast cancer
(TBNC) (Figure 4A). For the luminal B and HER2 groups, a
heterogeneous expression of SP-D was observed (Figures 4i,ii).
We also examined serial sections for the localization of HA
within the tumor microenvironment following histochemical
analysis of normal and breast cancer tissue specimens. As shown
in Figure 4i, Alcian blue staining highlighted the presence of
acid mucins, containing HA and sialic acid (42–44), in the
tumor stroma, around the tumor cells and was very faint in the
peritumoral mammary parenchyma in all the molecular classes
of breast cancer considered. The luminal B and HER2 specimens
were characterized by a variable SP-D expression within the
tumor. In the luminal B and HER2 groups, Alcian blue staining
also showed a greatly heterogeneous expression of HA. Thus,
a stronger staining for Alcian blue was evident where a lower
presence of SP-D was detected, suggesting that a modification
of ECM might be associated with a variable distribution of SP-D
(Figures 4A,G–L).
rfhSP-D Binds to High-Molecular-Weight
HA
Confirmation of the presence of HA in the breast cancer tissues
prompted us to examine if rfhSP-D binds to HA and can
modulate the nature of rfhSP-D–breast cancer cell interaction.
In direct binding ELISA, rfhSP-D bound to solid-phase
high-molecular-weight (1,500 kDa) HA in a dose-dependent
manner (Figure 5A). Immobilized rfhSP-D (20 µg/ml) alone as
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TABLE 1 | Flow cytometric analysis of apoptosis induction in breast cancer cells treated with 20 µg/ml of immobilized and solution-phase rfhSP-D for 24 h.













BT20 5 7 70 5 12 70
BT474 8 61 70 8 34 70
SKBR3 4 68 70 4 53 70
FIGURE 3 | Caspase activation in breast cancer cell lines following rfhSP-D
treatment at 24 h. Western blot analysis showed presence of cleaved caspase
3 at 17kDa in the cells treated with rfhSP-D for 24 h. (A) Western blot analysis
showed presence of cleaved caspase 9 at 37kDa (B), suggesting induction of
the intrinsic pathway.
well as HA (20 µg/ml)-bound rfhSP-D were then allowed to
interact with breast cancer cell lines. Cell adhesion assay was
performed by labeling the cells with the fluorescent probe FAST
DiI (Figure 5B). All three breast cancer cell lines (BT20, BT474,
and SKBR3) were able to adhere to HA, to rfhSP-D, and to
HA-bound rfhSP-D. rfhSP-D enticed a greater cell adhesion when
compared to HA alone or HA-bound rfhSP-D; all three cell lines
bound to similar extent (Figure 5B).
HA Binding Modulates the Ability of
rfhSP-D to Induce Apoptosis
The implication of HA–rfhSP-D interaction on apoptosis
induction in breast cancer cells was investigated (Figure 6A).
Breast cancer cells incubated with pre-coated HA, HA + rfhSP-
D, and rfhSP-D-only wells, along with untreated (cells only) cells,
were stained after 24 h with Annexin V/FITC; the quantification
of apoptosis was carried out using flow cytometry (Figure 6A).
Addition of HA to rfhSP-D reduced apoptosis induction by
∼45%. Since we noticed a reduced apoptosis induction by
HA+ rfhSP-D, we considered if rfhSP-D induced a proliferative
response in combination with HA. Thus, HA + rfhSP-D-treated
breast cancer cells were stained with mouse anti- Ki-67 antibody
to detect the percentage proliferation (Figure 6B). Ki-67 is a well-
known nuclear protein associated with active cell proliferation
and is expressed throughout the active cell cycle, including
G1, S, G2, and M phases. Addition of HA in rfhSP-D-treated
SKBR3 cells resulted in ∼30% cell proliferation (Figure 6B),
suggesting that HA negated pro-apoptotic effects of rfhSP-D
in breast cancer cell lines. In the case of BT474, only ∼47%
of proliferative cells were seen among rfhSP-D-treated BT474
cells, while HA + rfhSP-D-treated BT474 cells showed a higher
proliferation (∼95%) (Figure 6B). HA-only-treated BT474 cells
showed∼88% of Ki-67-positive cells, while∼66% of proliferative
cells were seen in HA-treated SKBR3 cells. However, proliferation
of BT20 cells was not affected by rfhSP-D or HA treatment,
suggesting that these cells continue to grow. These percentage
proliferations are compared to untreated control (cells only).
Given the presence of SP-D in the breast cancer tissues, we made
an attempt to purify SP-D from the culture supernatants of the
breast cancer cells on the assumption that breast cancer cells can
also be a likely source of SP-D in the tumor microenvironment.
We could purify SP-D only from BT474 cell culture (Figure 6C).
However, the purified SP-D was not able to induce apoptosis in
BT474 cells (Figure 6D).
rfhSP-D Treatment Upregulated Cell Cycle
Inhibitors and Induced p53-Dependent
Apoptosis
Activated p53 is a known mediator of DNA damage,
oxidative burst, cell cycle arrest, and induction of apoptosis.
Therefore, we analyzed the levels of activated p53 in rfhSP-
D-treated breast cancer cells. Increased levels of p53
phosphorylation at Ser15 was detected in rfhSP-D-treated
SKBR3 cells (Figure 7A), while downregulation was seen
in the BT20 cell line (Figure 7A), suggesting that p53
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FIGURE 4 | (Continued)
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FIGURE 4 | (i) SP-D and Hyaluronic acid (HA) presence in different histotypes of neoplastic breast (A–L), and normal ductal mammary epithelium (M–O). (A,D,G,J). A
high variability of SP-D expression between different histotypes is shown, although the positivity of the signal is always attributable to neoplastic cells, as can be
observed from the higher- resolution images in the right part of the figure (B,E,H,K). AEC (red) chromogen was used to visualize the binding of anti-human SP-D
antibodies. (C,F,I,L,O) Histochemical staining with Alcian Blue highlighted HA distribution in breast cancer and normal tissue sections; in particular, the staining was
visible in tumor-associated stroma. (ii) Immunohistochemical and histochemical analysis in Luminal-B and Her2+/ER-/PR- breast carcinoma sections of SP-D (A–F)
and HA (G–L) expression, respectively (B). A high variability of SP-D and HA expression within the same isotypes is shown. It is possible to notice a slight inverse
correlation between SP-D and HA expression. AEC (red) chromogen was used to visualize the binding of anti-human SP-D antibodies, whereas histochemical staining
with Alcian Blue highlighted HA distribution.
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FIGURE 5 | Interaction of rfhSP-D with HA. Binding of varied concentrations of rfhSP-D to HA (20 µg/ml) by ELISA (A). The effects of rfhSP-D on Breast cancer cell
lines adhesion (B). Breast cancer cells were labeled with the FAST DiI fluorescent dye and allowed to adhere to 96 microtiter wells pre-coated with HA, rfhSP-D, and
BSA. The data is expressed as the mean of three independent experiments. The adhesion of cells was measured after 35 minutes of incubation at 37◦C under 5%
CO2. Results are expressed as adhesion percentage with reference to a standard curve established using an increasing number of FAST DiI -labeled cells. The data is
expressed as the mean of three independent experiments (n = 3) done in triplicates ± SEM. Statistical significance was established using the unpaired one-way
ANOVA test (**p < 0.01 and ***p < 0.001). The statistical analysis was performed between rfhSP-D and HA + rfhSP-D -treated breast cancer cells.
upregulation may also have contributed to p53-dependent
apoptosis induction in SKBR3 cells. In addition, increased
transcript levels of p21 and p27 were observed in rfhSP-
D-treated BT474 and SKBR3 cell lines (Figure 7B) at
12-h time point, suggesting the possibility of cdc2–cyclin
B1 reduction leading to G2/M cell cycle arrest. Reduced
levels of phosphorylated p53, caspase 3, p21, and p27 were
observed in HA + rfhSP-D-treated SKBR3 and BT474 cells
(Figures 7A,B), suggesting reduced apoptosis induction by
the addition of HA. In the case of BT20, no significant
difference was found in terms of p21 and p27 mRNA
expression levels between rfhSP-D- and HA + rfhSP-D-treated
BT20 cells.
DISCUSSION
In this study, we show that rfhSP-D binds to all breast
cancer cell lines tested: BT20 (ER−/PR−/HER2−), BT474
(ER+/PR+/HER2+), and SKBR3 (ER−/PR−/HER2+). However,
the receptor, SP-D is binding to on the cancer cell surface, is
not yet known. Exogenous treatment with rfhSP-D reduced cell
viability of BT474 and SKBR3 cell lines and induced apoptosis
at 24 h. Cell viability and apoptosis assays were carried out
using varied concentrations of rfhSP-D (5, 10, and 20 µg/ml)
and different time points (12, 24, and 48 h), but only 20 µg/ml
concentration of rfhSP-D was effective in inducting the optimal
cell viability reduction and apoptosis induction at 24 h. rfhSP-D-
treated BT474 and SKBR3 cells showed a significant reduction
in viable cells compared to untreated control (cells only), as
evident from Trypan blue exclusion and MTT assay (data not
shown). However, no effect of rfhSP-D was seen on the triple-
negative (BT20) cell line in terms of cell viability. Recent studies
have shown the ability of the CRD region of human SP-D to
interact with N-glycans of EGFR, resulting in downregulation
of EGF signaling in A549 cell line (23). It is likely that rfhSP-
D-mediated apoptosis is due to HER2 expression on BT474 and
SKBR3 cells; a lack of it seems to increase BT20 cells resistant
Frontiers in Immunology | www.frontiersin.org 11 July 2020 | Volume 11 | Article 1171
Murugaiah et al. Innate Immune Surveillance by SP-D
FIGURE 6 | Apoptosis induction in BT20, BT474, and SKBR3 cell lines following HA challenge in the presence and absence of rfhSP-D (A). The data were expressed
as the mean of three independent experiments (n = 3). A significant difference was seen among treated and untreated samples, as made evident by the shift in the
fluorescence intensity. Staurosporine (1 µM/ml) was used as a positive control. Proliferative effects of rfhSP-D treatment on BT474 and SKBR3 breast cancer cell lines
(B). BT474 and SKBR3 cells were seeded in wells pre-coated with HA, HA + rfhSP-D, and rfhSP-D alone. The percentage of proliferative cells was evaluated by
staining with mouse anti-human KI-67 antibody, and KI-67-stained cells were measured via flow cytometry. The data were generated from at least three independent
(Continued)
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FIGURE 6 | experiments (n = 3) and presented as mean ± SD (*p < 0.1, **p < 0.01, and ****p < 0.0001). The statistical analysis was performed between rfhSP-D
and HA + rfhSP-D-treated breast cancer cells. The secretion levels of FL-SP-D were confirmed and analyzed via western blotting (C). Culture medium collected from
BT20, BT474, and SKBR3 cell lines was passed through a maltose Agarose column, and the eluted fractions were validated via western blotting; FL-SP-D was
detected at ∼43 kDa only for BT474. Both BT20 and SKBR3 cell lines did not secrete any FL-SP-D. Secreted FL-SP-D by BT474 was tested for its ability to induce
apoptosis (D). No effect of secreted FL-SP-D was seen in terms of cell viability and apoptosis induction.
FIGURE 7 | Intracellular signaling to show phosphorylation of p53 in rfhSP-D-treated BT20 and SKBR3 cell lines (A). Breast cancer cell lines were allowed to adhere
to HA or HA-bound rfhSP-D, and the phosphorylation status of p53 was evaluated using total cell lysates with a PathScan Antibody Array Kit (Cell Signaling). Data
were generated from at least three independent experiments and presented as mean ± SD. rfhSP-D treatment resulted in upregulation of p21 and p27 cell cycle
inhibitors (B). BT20, BT474, and SKBR3 (0.4 × 106) cells were seeded in a six-well-plate pre-coated with rfhSP-D and HA + rfhSP-D. The treated cells were lysed
and pelleted down. The pelleted cells were subjected to RNA isolation, followed by cDNA synthesis and qPCR. The comparative quantification method was
performed to calculate the efficiencies of each gene for each individual PCR and is based on the second differential maximum method or takeoff analysis. The takeoff
results obtained with p21/p27 primers were normalized with the housekeeping gene TBP. qPCR assay was conducted in triplicates, and error bars represent ± SEM.
Unpaired one-way ANOVA test was used to determine the significance; *p < 0.05, **p < 0.01, and ***p < 0.001 (n = 3). The statistical analysis was performed
between rfhSP-D and HA + rfhSP-D-treated breast cancer cells.
to the rfhSP-D effect. Whether HER2 is implicated in mediating
rfhSP-D-induced apoptosis is under investigation.
The ability of rfhSP-D to induce apoptosis at 24 h in SKBR3
and BT474 cell lines was evident from a significant increase
in the number of Annexin V-/PI-positive breast cancer cells
examined via flow cytometry and fluorescence microscopy. The
cell surface of the healthy cells is composed of asymmetrically
distributed lipids on the inner and outer surfaces of the plasma
membrane. PS is one of these lipids, which is restricted to the
inner surface of the plasma membrane and, thus, is only exposed
to the cytoplasm of the cell. However, when apoptosis is triggered
by stress factors, lipid asymmetry is lost, and PS translocates to
the outer leaflet of the plasmamembrane (45). Annexin V is a 36-
kDa calcium-binding intracellular protein that binds to PS (45).
Thus, Annexin V can also stain cells undergoing necrosis due to
a ruptured membrane that permits the access of Annexin V to
the entire plasma membrane. Western blotting analysis of rfhSP-
D-treated BT474 and SKBR3 breast cancer cells revealed cleavage
of caspases 9 and 3 at 12-h treatment. Caspases are well-known
cysteine-aspartic proteases that play a crucial role in apoptosis;
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caspase 9 is triggered by cellular stress (e.g., DNA damage), via
its binding to apoptotic protease-activating factor 1 (Apaf-1).
Apaf-1/procaspase 9, in turn, triggers executioner caspases 3 and
7 (46). Caspase 3 is an essential apoptotic executor, triggered by
endoproteolytic cleavage at Asp175, which leads to inactivation
of PARP (a known marker of apoptosis) (45, 47). These findings
indicated that rfhSP-D-mediated apoptosis induction in SKBR3
and BT474 cell lines is likely to occur via the intrinsic apoptotic
pathway (48). Recently, an integral role of rfhSP-D in innate
immune surveillance against prostate cancer has been reported.
rfhSP-D-mediated apoptosis has been suggested to take place
by two distinct mitochondrial apoptotic mechanisms (19). It is
also possible that p53 upregulation in rfhSP-D-treated BT474
and SKBR3 cell lines may lead to downregulation of the pAkt
pathway, resulting in increased levels of Bad and Bax, triggering
the release of cytochrome c, caspase 9 cleavage, and apoptosis
induction. Furthermore, previous studies have also reported the
interaction of SP-D with HMGA1, CD14, CD91–calreticulin
complex, SIRPα, and EGFR (19, 22, 23, 49). The involvement
of SP-D with these key molecules is likely to be relevant as a
part of a possible mechanism/receptor through which rfhSP-
D is likely mediating its apoptotic functions on breast cancer
cells. As reported in previous studies, the CRD of SP-D can
interact with pattern recognition receptors TLR-2, TLR-4 (50),
and CD14 (22), which may block pro-inflammatory and pro-
survival downstream signaling on breast cancer cells. However,
further investigation is crucial to understand the involvement of
CRD and its possible interacting partners involved in triggering
the downstream mechanism of apoptosis induction.
During the development of breast tumorigenesis, the
tumor cells interact with surrounding stroma to create a
tumor microenvironment, supporting the growth, survival, and
invasion of cancer cells. The ECM is an essential constituent of
the niche, leading to progression of malignant tumor formation
and proliferation. ECM is composed of a wide range of
proteoglycans and glycosaminoglycans, which offers a structural
support and promotes tissue organization, thus contributing to
cell survival, proliferation, invasion, angiogenesis, and immune
cell infiltration (35, 51). HA is one of the specific components of
ECM, which is synthesized as a large linear anionic polymer at
the cell surface. The role of HA during inflammation-mediated
breast cancer has been established (52, 53). In vitro studies have
reported the ability of HA to regulate tumor cell migration and
invasion and tumor growth and progression using in vivomodels
(39). Synthesis and accumulation of HA have been detected in
invasive breast cancer cells compared to normal breast epithelial
tissues (39). Additionally, HA synthase 2 facilitates invasion in
breast cancer cells (51). Furthermore, tumor cells overexpressing
HA synthase 2 have been shown to enhance angiogenesis and
stromal cell recruitment, suggesting that increased levels of
HA in the tumor stroma support breast carcinoma (51). Pro-
tumorigenic roles of increased HA expression in breast tumors
and possible mechanisms through whichHAmight trigger tumor
proliferation are areas of great interest. Therefore, we examined
the interaction between rfhSP-D and HA and its implication on
the adhesion and proliferation of BT20, BT474, and SKBR3 breast
cancer cells.
Direct binding ELISA revealed that rfhSP-D bound to HA
in a dose-dependent manner. The ability of breast cancer cells
to interact with HA-bound rfhSP-D was examined via a cell
adhesion assay. Cell adhesion assay was performed to assess
the effect of rfhSP-D or HA treatment on the ability of breast
cancer cells to adhere. A greater cell adhesion binding pattern
was observed with rfhSP-D alone, when compared to HA-bound
rfhSP-D orHA alone. Thismay be due to the interaction of rfhSP-
D-treated cells with apoptotic-related receptors and pathways
leading to apoptosis induction. Apoptotic and proliferative assays
were also performed to investigate the effect of HA-bound rfhSP-
D in comparison to rfhSP-D alone. SKBR3 cells seeded on HA-
bound rfhSP-D resulted in an increased cell proliferation (1.7-
fold), when compared to rfhSP-D alone. In the case of rfhSP-D-
treated BT474 cells, addition of HA resulted in a two-fold increase
of proliferative cells. However, the percentage of proliferating
cells in the presence of HA-bound rfhSP-D was not significantly
different from that in HA alone or untreated SKBR3 and BT474
cells. Therefore, these findings suggest that pro-apoptotic effects
of rfhSP-D are modulated by HA addition. However, there
was no significant difference in the proliferation of BT20 cells
among all the conditions, suggesting that these cells continue
to grow and are not affected by rfhSP-D treatment alone or in
conjunction with HA. It is also possible that addition of HA
may modulate the interaction of rfhSP-D-treated cells with pro-
apoptotic signaling pathways, thereby restricting the possibility
of apoptosis induction. Thus, addition of HA could facilitate cell
proliferation by interacting with proliferative signaling cascades
(e.g., Ras-ERK and PI3K-Akt). Even though breast cancer tissues
express SP-D (Figures 4i,ii), the presence of HAwithin the breast
tumor microenvironment seems to provide a self-protective coat,
thus negating the anti-tumorigenic properties of SP-D. Since
BT474 and SKBR3 cells treated with rfhSP-D undergo apoptosis
and addition of HA to rfhSP-D enhances cell proliferation, it
is likely that breast cancer cells can use HA in their tumor
microenvironment as an escape mechanism from apoptosis
induction triggered by rfhSP-D.
To further understand the mechanism of apoptosis
induction by rfhSP-D treatment, the likely signaling pathways
involved in tumor adhesion, proliferation, and cell death were
analyzed. rfhSP-D treatment resulted in increased levels of p53
phosphorylation (at Ser15), possibly mediated by oxidative stress
caused by rfhSP-D (17, 49). p53 is an essential transcriptional
modulator of apoptosis and plays a crucial role in cellular
response to DNA damage as well as other genomic alterations.
Phosphorylated p53 and increased levels of P21/P27 expression
may cause inactivation of cyclin B–cdc2 complexes that are
crucial in regulating G2/M cell cycle transition, causing DNA
repair or induction of apoptosis (17). However, decreased levels
of caspase 3 and p53 were detected in HA + rfhSP-D-treated
cells, possibly suggesting its resistance to apoptosis by addition
of HA. Although the p21 trigger is p53 dependent in certain
events such as DNA damage, there are several scenarios in which
p21 expression is independent of p53 status, such as normal
tissue development and differentiation. p21 can lead to tumor
evolution directed toward tumor growth by slowing down the
accumulation of DNA damage. Induction of p21 expression has
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been shown to be crucial for promoting motility of tumor cells
and tumorigenesis. Due to controversial roles of p21, it can be
considered as an oncogenic protein and/or tumor suppressor,
depending on its cytoplasmic localization. The dual roles of
p21 as an oncogenic or tumor suppressor make it difficult to
study the mechanisms involved in p53–p21-mediated apoptosis
induction or cancer progression.
Targeting HA synthesis, accumulation, degradation, or HA–
receptor interaction represents a potential therapeutic approach
for treatment of breast and other cancers. The use of 4-
MU to inhibit HA synthesis has been shown to reduce
breast cancer proliferation and migration (54–57). 4-MU
treatment has also been shown to inhibit intracellular and
cell surface HA (57), in addition to suppression of Akt
phosphorylation. Use of hyaluronidases to degrade HA in the
tumor microenvironment has also been considered as a potential
therapeutic approach for cancer. Bacteriophage hyaluronidase
has been shown to effectively inhibit growth, migration, and
invasion of breast cancer cells (58). Hyaluronidase treatment has
also shown promising outcomes in pancreatic cancer in clinical
trials (59–61). Furthermore, recombinant human hyaluronidase
(rHUPH20) has been shown to improve drug delivery of
antibody-based trastuzumab targeted therapy in HER2+ breast
cancer (62). A recent study has shown that HA degradation
by pegvorhyaluronidase (PVHA) can remodel the TME in a
murine model of breast cancer so as to increase the uptake of
anti-ProgrammedDeath-Ligand 1 (PD-L1) therapeutic antibody.
PVHA treatment coincided with a dramatic effectiveness of anti-
PD-L1 antibody in reducing the tumor growth (63).
Involvement of rfhSP-D and its associated pro-apoptotic
properties in cancer models might be a novel therapeutic agent
to target multiple cellular signaling pathways, including tumor
cell survival factors, transcriptional factors, protein kinases, and
pro-apoptotic gene signatures. The mechanism which enables
rfhSP-D to induce apoptosis and inhibit tumor cell proliferation
is tumor specific due to the differential effects on the cell
types and probably expression of putative receptors. The nature
of interaction between HA + rfhSP-D and cellular receptors
is currently under investigation. The function of SP-D in the
biology of cancer is complex and is strongly dependent on the
tumor microenvironment. As SP-D and HA are overexpressed
in breast cancer and other carcinomas, targeting both HA and
SP-D is clinically relevant to inhibit HA-mediated intracellular
signaling that negates the pro-apoptotic role of rfhSP-D. It is
important to note that FL-SP-D purified from BT474 was not
able to induce apoptosis in any of the three breast cancer cell
lines. The plausible reasons could be that the tumor cells produce
a dysfunctional protein owing to mutations, protein misfolding,
and/or altered oligomerization.
In conclusion, rfhSP-D treatment was able to induce
apoptosis in BT474 and SKBR3 cell lines involving the
intrinsic apoptotic pathway, while having no effect on the
triple-negative BT20 cell line. In addition, HA-bound rfhSP-
D was able to restore cell growth, suggesting that these
breast cancer cells may use HA as an escape mechanism to
overcome pro-apoptotic effects of rfhSP-D. The mechanisms by
which HA-bound rfhSP-D restores cell proliferation are yet to
be elucidated.
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